Cantargia Investor Relations Material
Latest events
Q2 2025
Cantargia
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cantargia
Access all reports
Cantargia AB, a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. Its lead product is CAN04, an antibody directed the interleukin-1 receptor accessory protein that targets cancer cells that express IL1RAP on their surface; and CAN04 is currently being developed in two clinical programs, one focusing on treatment of lung cancer and another on treatment of pancreatic cancer. Cantargia AB was founded in 2010 and is based in Lund, Sweden.
Key slides for Cantargia
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CANTA
Country
🇸🇪 Sweden